Peptide Dosage Chart & Guide

The following peptide dosage chart compiles commonly referenced research dosage ranges for the most popular peptides. This peptide dosing guide covers subcutaneous, oral, and intranasal compounds with typical dose ranges, frequency, and timing. All dosages are for research reference only — consult a healthcare provider before using any peptide.

Reading the chart: GLP-1 metabolic peptides (semaglutide, tirzepatide, retatrutide, cagrilintide) are titrated — you start at a low dose and step up slowly, so they are shown as start → target. Never begin at the target dose. Every dose in this chart is a research reference, not a prescription.

Peptide	Typical Research Dose	Frequency	Route	Timing Notes
Semaglutide	0.25 mg/week (start) → 2.4 mg/week (target)	1x weekly	SubQ (or oral)	Mandatory titration — increase roughly every 4 weeks. Oral (Rybelsus) is 3 mg/day → 7–14 mg/day
Tirzepatide	2.5 mg/week (start) → 5–15 mg/week (target)	1x weekly	SubQ	Ramp no faster than 2.5 mg every 4 weeks. 2.5 mg is a warm-up, not a treatment dose
Retatrutide	1 mg/week (start) → up to 12 mg/week (trial doses)	1x weekly	SubQ	Investigational — not FDA-approved. Escalated in ~monthly steps in Phase 2 trials
Cagrilintide	0.3 mg/week (start) → 2.4 mg/week (target)	1x weekly	SubQ	Amylin analog; titrated upward. Paired with semaglutide in CagriSema (2.4 mg + 2.4 mg)
BPC-157	200-500 mcg/day	1-2x daily	SubQ or oral	Can split into AM/PM doses. SubQ near injury site when targeting specific area
TB-500	2-5 mg/week (loading), 2 mg/week (maintenance)	2-3x weekly	SubQ	Loading phase (4-6 weeks) followed by lower maintenance dose
GHK-Cu	100-500 mcg/day (injectable) or 1-3% topical	1x daily	SubQ or topical	Topical for skin/hair. Injectable for systemic effects
Sermorelin	100-300 mcg/day	1x daily	SubQ	Before bed on empty stomach (aligns with GH surge)
Ipamorelin	100-300 mcg/dose	2-3x daily	SubQ	On empty stomach. Often combined with CJC-1295
CJC-1295 (no DAC)	100-300 mcg/dose	2-3x daily	SubQ	Often stacked with ipamorelin for synergistic GH release
CJC-1295 (with DAC)	1-2 mg/week	1-2x weekly	SubQ	DAC extends half-life, allowing less frequent dosing
Tesamorelin	2 mg/day (trial dose) — or 1.4 mg (Egrifta SV) / 1.28 mg (Egrifta WR)	1x daily	SubQ	Evening administration. All three doses deliver the same amount of drug: the FDA labels state the 1.4 mg and 1.28 mg branded doses have bioavailability comparable to 2 mg of the original formulation, which absorbs less well. Every pivotal trial used 2 mg/day of that original plain formulation, so 2 mg is the figure the evidence rests on
AOD-9604	250-500 mcg/day	1x daily	SubQ	Morning on empty stomach (fasted state)
PT-141 (Bremelanotide)	1.75 mg/dose (FDA-approved dose)	As needed, max 1x per 24 hours	SubQ	45 min before activity. Max 8 doses/month. FDA-approved for HSDD
MK-677	10-25 mg/day	1x daily	Oral	Can cause hunger — many take before bed to sleep through appetite spike
Semax	200-600 mcg/day	1-3x daily	Intranasal	Morning dosing preferred. 200 mcg is the standard Russian clinical dose
Selank	250-750 mcg/day	1-3x daily	Intranasal	Can be taken morning or evening. Anxiolytic effects
KPV	200-500 mcg/day	1-2x daily	SubQ or oral	Oral for gut inflammation. SubQ for systemic effects
Epitalon	5-10 mg/day	1x daily (10-20 day courses)	SubQ	Cycled 2-3x per year in 10-20 day protocols

Use our peptide calculator to convert these doses into syringe measurements based on your reconstitution concentration, or the dosage calculator for body-weight-adjusted ranges.

Note: All peptide dosages listed in this chart are based on published research protocols and clinical trial data. They are provided for educational reference only and do not constitute medical advice. Individual dosing should be determined by a qualified healthcare provider based on your specific circumstances.

• Start low: Begin at the lower end of the research dose range to assess tolerance before increasing
• Consistency matters: Most peptide effects are cumulative. Consistent daily dosing over weeks is more important than any single dose
• Cycling: Many protocols include rest periods (e.g., 5 days on, 2 days off, or 4 weeks on, 2 weeks off) to prevent receptor desensitization and maintain effectiveness
• Empty stomach: GH secretagogues and fat-loss peptides are typically more effective on an empty stomach (no food for 2+ hours before and 30 minutes after)
• Timing with GH pulse: For peptides that stimulate GH release, evening/bedtime dosing aligns with the body's natural nighttime GH surge

Some peptide protocols reference doses on a per-kilogram body weight basis (mcg/kg). This is particularly common in animal research that is extrapolated to human dosing. For research peptides, most human protocols use fixed doses rather than weight-adjusted doses.

Notable exceptions:

• BPC-157: Some research references 1-10 mcg/kg/day, though most human protocols use fixed doses of 200-500 mcg
• GLP-1 agonists: FDA-approved doses are fixed (not weight-based) but are titrated up over time

Our dosage calculator can adjust standard ranges for body weight if you prefer weight-based dosing.

Many peptide protocols involve stacking two or more compounds for synergistic effects. When combining peptides, each compound is dosed at its standard individual range — there is generally no need to reduce doses when stacking unless your healthcare provider advises otherwise.

Common stacking examples:

• Healing stack (BPC-157 + TB-500): BPC-157 at 200–500 mcg/day + TB-500 at 2–2.5 mg twice weekly. These peptides target complementary repair pathways and are commonly combined for tendon and joint injuries
• GH optimization (CJC-1295 + Ipamorelin): Both at 100–300 mcg, combined in the same syringe and injected together before bed. The GHRH analog (CJC-1295) and secretagogue (ipamorelin) produce a larger GH pulse together than either alone. See the GH optimization stack
• Fat loss stack (AOD-9604 + Ipamorelin): AOD-9604 at 250–500 mcg in the morning (fasted) + ipamorelin at 200–300 mcg before bed. Different timing optimizes each compound's mechanism

Timing separation: Some peptides should be taken at different times of day for optimal absorption or to avoid interaction. GH secretagogues require an empty stomach, while BPC-157 is timing-flexible. When in doubt, separate different peptide injections by at least 15–30 minutes.

Use the stack builder tool to explore evidence-based combinations, or browse all peptide stacks for curated protocols with exact dosing schedules.

Some vials contain two or more peptides pre-mixed together — the most common being GLOW (GHK-Cu + BPC-157 + TB-500). A blend is not a single compound with its own dose; it is several peptides sharing one vial, so you dose it by the amount of each component the label lists, not by a generic "blend dose."

The key rule: dose off your specific vial's stated milligrams. Blend ratios differ between suppliers, so two vials both labeled "GLOW" can contain different amounts of each peptide. A GLOW vial commonly lists roughly 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 (70 mg total), but always read your own label.

Worked example: a vial lists 70 mg total peptide and you add 2 mL of bacteriostatic water. That gives 70 ÷ 2 = 35 mg/mL of total blend. A 0.10 mL draw is 10 units on a standard U-100 insulin syringe and delivers 3.5 mg total — roughly 2.5 mg GHK-Cu, 0.5 mg BPC-157, and 0.5 mg TB-500 at the assumed ratio.

Because the components are fixed in one vial, you cannot dose them independently — increasing your draw to get more BPC-157 also raises your GHK-Cu and TB-500 proportionally. If you need to control each peptide separately, single-compound vials give you that flexibility. Run your blend's numbers through the reconstitution calculator, and see the full GLOW blend breakdown for what the evidence does and does not support.

Titration means starting at a lower dose and gradually increasing to the target dose. This approach minimizes side effects and helps identify the minimum effective dose for each individual.

Why titrate?

• Reduces the severity of initial side effects (e.g., nausea with semaglutide, water retention with GH secretagogues)
• Allows assessment of individual sensitivity — some people respond strongly to lower doses
• FDA-approved peptides (semaglutide, tirzepatide, tesamorelin) all have specific titration schedules built into their prescribing information

Titration guidelines by peptide category:

• GLP-1 agonists (semaglutide, tirzepatide): Follow the manufacturer's titration schedule exactly. Semaglutide starts at 0.25 mg/week and increases monthly. Tirzepatide starts at 2.5 mg/week. Skipping titration causes severe GI side effects
• GH secretagogues (ipamorelin, sermorelin): Start at the low end of the range (100 mcg) for the first week. Increase by 50–100 mcg per week until reaching your target dose
• Healing peptides (BPC-157, TB-500): These are typically well-tolerated and may not require titration at standard doses. Start with one injection per day before moving to twice daily if your protocol calls for it

Track your response in a simple journal noting dose, timing, injection site, and any effects or side effects. This helps identify your personal optimal dose.

The chart above covers general ranges, but each peptide has nuances — loading phases, titration schedules, cycle lengths, and timing windows that affect results. These dedicated dosage guides go deeper:

• BPC-157 dosage guide — oral vs injectable protocols, injury-specific dosing, and cycle length
• Semaglutide dosage guide — titration schedule, oral vs injectable doses, and maintenance protocols
• TB-500 dosage guide — loading vs maintenance phases, reconstitution volumes, and stacking doses
• Ipamorelin dosage guide — timing with meals, CJC-1295 stacking doses, and cycling
• CJC-1295 dosage guide — DAC vs no-DAC dosing, frequency differences, and combination protocols
• GHK-Cu dosage guide — topical vs injectable dosing, skin protocols, and systemic use
• AOD-9604 dosage guide — fasted-state timing, dose range, and fat-loss-specific protocols
• Retatrutide dosage guide — clinical trial dose escalation schedule and research protocols

Skip the math — our free calculators handle reconstitution volumes, syringe units, and body-weight adjustments automatically:

• Peptide Dosage Calculator — enter your compound, body weight, and target dose to get personalized dosing ranges and schedules
• Reconstitution Calculator — enter your vial size and BAC water volume to get exact syringe unit measurements for any dose
• BAC Water Calculator — determine how much bacteriostatic water to add based on your desired concentration and dose precision

The most common practical question after reconstitution is "how many units do I draw?" The answer depends entirely on your concentration (mg or mcg per mL), which is set by how much bacteriostatic water you added. On a standard U-100 insulin syringe, 100 units = 1 mL, so 10 units = 0.1 mL.

The formula is: units to draw = (your dose ÷ concentration) × 100. The table below shows a common setup — a 5 mg vial reconstituted with 2 mL, giving 2,500 mcg/mL:

Target Dose	Volume (mL)	Units (U-100 syringe)
250 mcg	0.10 mL	10 units
500 mcg	0.20 mL	20 units
750 mcg	0.30 mL	30 units
1,000 mcg (1 mg)	0.40 mL	40 units

Change the water volume and every number changes — adding 1 mL instead of 2 mL doubles the concentration and halves the units for the same dose. That is why you should never copy someone else's "units" number without matching their vial size and water volume. The reconstitution calculator does this conversion for any vial size, water volume, and dose automatically, and the reconstitution guide walks through the mixing step by step.

The right peptide — and the right dose — depends on what you are trying to achieve. These goal-specific guides explain which compounds and dose ranges match each objective:

• Peptides for weight loss — GLP-1 agonist titration schedules, AOD-9604 protocols, and combination approaches
• Peptides for muscle growth — GH secretagogue dosing for body composition, stacking schedules, and cycling
• Peptides for healing — BPC-157 and TB-500 dosing for tendon, ligament, and post-surgical recovery
• Peptides for anti-aging — epitalon cycling, GHK-Cu protocols, and GH optimization dosing for longevity

Some suppliers label products with codes or in-house names (letters and numbers, or blend names) rather than the actual peptide. You cannot dose a code — you can only dose a known compound at a known amount. Before drawing anything, work out exactly what is in the vial and how much.

1. Identify the actual compound. Match the coded name to the real peptide and confirm the milligrams per vial. GLP-1 products are the most commonly relabeled — check whether the code maps to semaglutide, tirzepatide, or retatrutide, since their dose ranges are completely different. If a "blend" name is used, find out which individual peptides and amounts it contains (see dosing blends above).
2. Verify it with a batch-specific COA. The dose you calculate is only as good as the stated contents. A batch-matched, third-party Certificate of Analysis confirms the vial actually holds the peptide and mass on the label — purity and mislabeling vary widely in the research-peptide market, and this is especially true for unapproved compounds like retatrutide. Our guide to evaluating a peptide source explains what a real COA should show.
3. Dose by the verified compound, not the label's suggested "protocol." Once you know the real peptide and confirmed milligrams, use that compound's research range from the chart above — not a generic frequency printed on the vial. Vendor label instructions (e.g. "3–5x weekly") are marketing conventions, not clinically validated doses.

If you cannot identify the compound or obtain a batch-specific COA, you do not have enough information to dose safely — the answer is to stop, not to guess.

Even experienced users make dosing errors that reduce effectiveness or increase side effects. Here are the most common mistakes and how to avoid them:

• Skipping GLP-1 titration: Starting semaglutide or tirzepatide at a full dose instead of following the titration schedule is the most common and most consequential dosing mistake. Severe nausea, vomiting, and diarrhea result from skipping the ramp-up period. These drugs require 12–16 weeks of gradual dose increases for a reason
• Eating before GH secretagogues: Food — especially carbohydrates and fats — blunts the GH response from secretagogues like ipamorelin and sermorelin by up to 70%. Ensure a 2-hour fasting window before injection and at least 30 minutes before eating afterward
• Incorrect concentration calculation: The most dangerous math error is confusing mg with mcg (1 mg = 1,000 mcg). A 5 mg vial reconstituted with 2 mL yields 2,500 mcg/mL — not 2.5 mcg/mL. Use the peptide reconstitution calculator to eliminate calculation errors
• Inconsistent dosing schedule: Peptide effects are cumulative. Skipping days or dosing at irregular times reduces effectiveness. Set a consistent daily alarm for time-sensitive peptides. For BPC-157 and TB-500, consistency over weeks matters more than any single dose
• Ignoring syringe dead space: Standard syringes retain 0.02–0.05 mL of solution in the needle hub after injection (dead space). For concentrated peptides, this can mean losing 5–10% of each dose. Low dead space syringes minimize this waste. Factor dead space into your dosing math or use the dosage calculator
• Taking the same dose indefinitely: Some peptides, particularly GH secretagogues, benefit from cycling (e.g., 5 days on / 2 off) to prevent receptor desensitization. Without cycling, the same dose produces diminishing returns over time. See the dosing principles section for cycling guidance